Virtual Library
Start Your Search
Rolandas Zablockis
Author of
-
+
EP1.01 - Advanced NSCLC (ID 150)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.01-60 - LENT Prognostic Score for Lung Cancer in the Presence of Malignant Pleural Effusion (ID 2556)
08:00 - 18:00 | Author(s): Rolandas Zablockis
- Abstract
Background
LENT scoring system is the first validated prognostic score in non-selected malignant pleural effusion (MPE), although its significance in MPE secondary to lung cancer remains unclear.
Method
85 consecutive patients (59% male, mean age 67±12yrs) with MPE secondary to lung cancer were enrolled. First episode of MPE presented a new cancer diagnosis in 71% of cases, 29% of MPE were diagnosed on disease progression. Histology types were: adenocarcinoma – 71 (83.5%), small cell carcinoma – 10 (11.8%), NOS – 4 (4.7%). LENT score was calculated on the day of MPE diagnosis confirmed.
Result
53 (62%) patients presented moderate risk category by LENT score, and 32 (38%) – high risk category. Mean LENT score was 4 (2–6), median (IQR) survival – 70 (32–281) days.
The patients with a moderate risk LENT score had a median (IQR) survival of 147 (70–423) days, those with high risk LENT score – 34 (31–41) days.
The ROC analysis showed no significant difference between LENT score and ECOG PS at 1, 3 and 6 months at predicting survival time (p>0.05).
MPE group that presented primary cancer diagnosis had a median (IQR) survival of 75 (31-318) days and MPE group that presented disease progression had a median (IQR) survival of 63 (37–185) days, there were no significant difference between these groups.
Conclusion
Our study meets literature data for LENT score predicting survival prognosis in malignant pleural effusion. However, our study showed no superiority of LENT score over ECOG PS.